Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic-ecollection
Document type Editorial
PubMed
32269965
PubMed Central
PMC7109439
DOI
10.3389/fonc.2020.00377
Knihovny.cz E-resources
- Keywords
- clinical trial designs, drug models, pediatric oncology, personalized medicine, personalized precision pediatric oncology, precision oncology, trial models,
- Publication type
- Editorial MeSH
Central European Institute of Technology Masaryk University Brno Czechia
CSTS Health Care Toronto ON Canada
Department of Clinical Trials Masaryk Memorial Cancer Institute Brno Czechia
Department of Laboratory Medicine Masaryk Memorial Cancer Institute Brno Czechia
Department of Pathology University Hospital Brno Brno Czechia
Department of Pediatric Oncology University Hospital Brno Brno Czechia
Department of Pediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czechia
Faculty of Medicine Masaryk University Brno Czechia
Floating Hospital for Children at Tufts Medical Center Boston MA United States
Editorial on the Research Topic Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize PubMed
See more in PubMed
Liu K, Meng XL. There is individualized treatment. Why not individualized inference? Annu Rev Stat Its Appl. (2016) 3:79–111. 10.1146/annurev-statistics-010814-020310 DOI
Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, et al. . Pharmacogenomics. Lancet. (2019) 394:521–32. 10.1016/S0140-6736(19)31276-0 PubMed DOI PMC
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. (2017) 359:j4530. 10.1136/bmj.j4530 PubMed DOI PMC
New Studies Question Whether Novel Anti-Cancer Drugs Are Worth Their Extra Cost [ESMO 2019 Press Release]. (2019). Available online at: https://www.esmo.org/Press-Office/Press-Releases/ESMO-Congress-anticancer-drugs-cost-Marino-Vokinger (accessed January 9, 2020).
Allison KH, Sledge GW. Heterogeneity and cancer. Oncology. (2014) 28:2–3. PubMed
Yoshioka A. Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. BMJ. (1998) 317:1220–3. 10.1136/bmj.317.7167.1220 PubMed DOI PMC
Bartholomew M. James Lind's treatise of the scurvy (1753). Postgrad Med J. (2002) 78:695–96. 10.1136/pmj.78.925.695 PubMed DOI PMC
Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials. (1988) 9:312–26. 10.1016/0197-2456(88)90046-3 PubMed DOI
Demlova R, Zdrazilova-Dubska L, Sterba J, Stanta G, Valik D. Host-dependent variables: The missing link to personalized medicine. Eur J Surg Oncol. (2018) 44:1289–94. 10.1016/j.ejso.2018.04.014 PubMed DOI
Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, Chen R, et al. . Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. (2012) 148:1293–307. 10.1016/j.cell.2012.02.009 PubMed DOI PMC
Lindsey JK, Lambert P. On the appropriateness of marginal models for repeated measurements in clinical trials. Stat Med. (1998) 17:447–69. 10.1002/(SICI)1097-0258(19980228)17:4<447::AID-SIM752>3.0.CO;2-G PubMed DOI
Nikles J, Mitchell G. N-of-1 trials in medical contexts. In: Nikles J, Mitchell G, editors. The Essential Guide to N-of-1 Trials in Health. Dordrecht: Springer Netherlands; (2015). p. 43–55. 10.1007/978-94-017-7200-6 DOI
Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, et al. . Future paradigms for precision oncology. Oncotarget. (2016) 7:46813–31. 10.18632/oncotarget.9488 PubMed DOI PMC
Stallard N, Miller F, Day S, Hee SW, Madan J, Zohar S, et al. . Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical J. (2017) 59:609–25. 10.1002/bimj.201500228 PubMed DOI PMC
Le Tourneau C, Gan HK, Razak ARA, Paoletti X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS ONE. (2012) 7:e51039. 10.1371/journal.pone.0051039 PubMed DOI PMC
Umukoro C. A Start, Stop, GO Story in AML – Gemtuzumab Ozogamicin (Mylotarg®). (2017) Available online at: https://amlglobalportal.com/medical-information/a-start-stop-go-story-in-aml-gemtuzumab-ozogamicin-mylotarg (accessed January 9, 2020).
